Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma

CONCLUSIONS: ITCs suggest that mosunetuzumab may lead to superior outcomes over tazemetostat (in EHZ2wild-type patients) and PI3K inhibitors and may be a promising alternative to re-challenging with a different anti-CD20 regimen in patients who relapse after ≥2 prior anti-CD20 lines. Although preliminary results somewhat favored CART therapies, limitations and uncertainties remain because of intrinsic differences in study design. Mosunetuzumab could thus be a promising treatment option for patients with RR FL after ≥2 prior therapies.PMID:37981564 | DOI:10.1016/j.clml.2023.09.007

Source: Clinical Lymphoma and Myeloma - November 19, 2023 Category: Cancer & Oncology Authors: Francesc Bosch John Kuruvilla Theodoros P Vassilakopoulos Danilo Di Maio Michael C Wei Marie-Helene Blanchet Zumofen Loretta J Nastoupil Source Type: research